Navigation Links
TargeGen Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients, and Presentations at ASH
Date:12/6/2007

SAN DIEGO, Dec. 6 /PRNewswire/ -- TargeGen, Inc. today announced that the Company's recently submitted IND for TG101348 is now active and the Company plans to initiate a multi-center clinical trial of TG101348, an internally discovered, oral, potent, and highly selective JAK2 inhibitor in January, 2008. Additionally, TargeGen announced that a series of presentations related to TG101348 will be made at the 2007 ASH Conference (Atlanta, December 8-11, 2007) by Company scientific staff and outside academic collaborators.
(Logo: http://www.newscom.com/cgi-bin/prnh/20030430/TARGEGENLOGO)

Scheduled ASH presentations include:

-- Catriona Jamieson -- Selective Inhibition of JAK2 Driven Erythroid

Differentiation of Polycythemia Vera

-- Animesh Pardanani & Ayalew Tefferi -- Primary Cell Experiments with

TG101348, A JAK2 Selective Small Molecule Inhibitor, in the Presence of

Myeloproliferative Disorder-Associated JAK2V617F, MPLW515K, or Exon 12

Mutations

-- Gerlinde Wernig & Gary Gilliland -- Efficacy of TG101348, a Selective

JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced

Polycythemia Vera, Session Type

-- Betty Tam -- TG101348: A Dual Acting JAK2/FLT3 Small Molecule Kinase

Inhibitor for the Treatment of AML

-- John Hood -- Prospective Identification of Resistance Mutants to the

JAK2 Inhibitor TG101348

The V617F mutation of JAK2 is implicated in the pathogenesis of certain myeloproliferative diseases, including polycythemia vera (PV), essential thrombocytopenia (ET) and primary myelofibrosis (PMF). In preclinical models of myeloproliferative diseases, TG101348, administered orally, was shown to reduce to reduce V617F expressing cell populations in a dose-dependant manner without adversely impacting normal hematopoeisis. The reduction of V
'/>"/>

SOURCE TargeGen, Inc.
Copyright©2007 PR Newswire.
All rights reserved

4

GOOD

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... YORK, Pa. , June 18, 2013 ... a U.S. based designer, developer and manufacturer of injectable ... new corporate website at www.unilife.com . The new ... information, with updates to occur on a regular basis. ... of Unilife, stated, "As an emerging global leader for ...
(Date:6/18/2013)... , June 18, 2013  Specialty Coating ... breakthrough in Parylene coating technologies: SCS microRESIST™ ... benefits of Parylene with antimicrobial properties to ... and components. (Logo: http://photos.prnewswire.com/prnh/20130618/DE33772LOGO ... (HAIs) increase and continue to pose a ...
(Date:6/18/2013)... 2013  In a letter to authorities at her hospital, ... Lake View, Iowa , writes that a policy ... is neither scientifically justified nor ethically sound. Her ... summer issue of the Journal of American Physicians and ... and an average of 36,000 patients per year die in ...
Breaking Medicine Technology:Unilife Launches New Corporate Website 2Specialty Coating Systems Announces New Antimicrobial Parylene Technology 2Mandated Flu Vaccine for Hospital Workers Ethically Questionable, Surgeon Writes 2
... Tenn., Nov. 18, 2011 MedSolutions , ... services, today announced the launch of its Implantable ... evidence-based guidelines to ensure the clinical appropriateness of ... With the cost of each ICD/CRT-D ...
... Md., Nov. 18, 2011 The U.S. Food and ... ) to treat patients with acute lymphoblastic leukemia (ALL), ... coli derived asparaginase and pegaspargase chemotherapy drugs used ... ) Acute lymphoblastic leukemia is a ...
Cached Medicine Technology:MedSolutions Launches Implantable Cardiac Defibrillator Program to Reduce Unnecessary Surgeries 2MedSolutions Launches Implantable Cardiac Defibrillator Program to Reduce Unnecessary Surgeries 3FDA Approves Erwinaze to Treat a Form of Leukemia 2FDA Approves Erwinaze to Treat a Form of Leukemia 3
(Date:6/18/2013)... Case Medical Center clinical researchers have launched an ... will evaluate the ability of a patient,s own ... stage peripheral arterial disease (PAD). , Led ... at University Hospitals Case Medical Center,s Harrington Heart ... Case Western Reserve University School of Medicine, the ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 The July 2013 ... Cheater’s Guide to Getting Beach Ready,” offers a list of ... look their best in a bathing suit this summer. The ... skin firming , smoothing cellulite , and more. (go ... Ourian, Medical Director of Epione Beverly Hills, “though I would ...
(Date:6/18/2013)... Healthcare Solutions , the parent ... today announced the appointment of Richard Leonardo to ... position, Leonardo will direct Healthcare Solutions’ national sales ... initiatives. , Recognized in the property and casualty ... more than 20 years of experience in business ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 David Connett, ... of Family Medicine for the College of Osteopathic Medicine ... Sciences has been elected president of the Osteopathic ... G. Brown Jr. appointed Connett, a 1984 alumnus of ... members recently elected Connett to the position during a ...
(Date:6/18/2013)... fat cells in the mammary gland appear to provide ... early in life, and the subsequent development of breast ... the July 2013 issue of the journal Cancer ... may be associated with an increased risk of certain ... the biology of social stress to cancer have been ...
Breaking Medicine News(10 mins):Health News:UH Case Medical Center launches novel clinical trial using stem cells to prevent amputation 2Health News:Skin Care – Getting Your Body Beach Ready 2Health News:Healthcare Solutions Appoints Richard Leonardo to Chief Sales Officer 2Health News:Fat cells in breast may connect social stress to triple-negative breast cancer 2Health News:Fat cells in breast may connect social stress to triple-negative breast cancer 3Health News:Fat cells in breast may connect social stress to triple-negative breast cancer 4
... TUESDAY, July 26 (HealthDay News) -- In the days ... antidepressants, such as bupropion or venlafaxine, nursing home residents ... a new study. Researchers found the increased risk ... dosage increase of their current prescription. "Our results ...
... Raymond and Ruth Perelman School of Medicine ... launching of a first-of-its-kind interdisciplinary center focused ... The Center will bring together, without institutional ... treating orphan diseases: establishing dedicated research support ...
... 26, 2011 An ophthalmologist at UT Southwestern Medical Center ... have a degenerative eye disease better track vision changes. ... perform an accurate self-test in less than 90 seconds, said ... "Many patients do not have timely eye exams ...
... FOR JULY 26, 2011] Antibiotic overuse and resistance have ... Following an outbreak of Clostridium difficile infections, which often ... Canada targeted physicians and pharmacists with an education campaign ... published in Clinical Infectious Diseases and now ...
... MONDAY, July 25 (HealthDay News) -- Parents of children with attention-deficit/hyperactivity ... younger than 10 years old with ADHD may be unable to ... found that while children with ADHD may look as if they ... and look both ways before crossing -- they aren,t always good ...
... gravel roads in Dunn County, North Dakota, they stir up ... wake contain such high levels of the mineral erionite that ... an increased risk of developing mesothelioma, a type of cancer ... is a natural mineral fiber that shares similar physical similarities ...
Cached Medicine News:Health News:Certain Antidepressants Linked to Falls in Nursing Homes 2Health News:Penn receives $10 million to create center for orphan disease research and therapy 2Health News:Penn receives $10 million to create center for orphan disease research and therapy 3Health News:UT Southwestern ophthalmologist helps develop device for monitoring degenerative eye disease 2Health News:Simple guidelines decreased unnecessary antibiotic use in Quebec, Canada 2Health News:Kids With ADHD Less Adept at Crossing the Street: Study 2Health News:Kids With ADHD Less Adept at Crossing the Street: Study 3Health News:New study finds cancer-causing mineral in US road gravel 2Health News:New study finds cancer-causing mineral in US road gravel 3
Bi-Directional doppler volume flowmeter....
... frequency and multigate transcranial ... and fitted with a ... for hemodynamic evaluation. Looki ... well for routine diagnosis ...
One channel, one gate transcranial Doppler that is diagnosis oriented with an advanced protocol editor, automatic report generator and a powerful examination data base....
One channel transcranial Doppler...
Medicine Products: